Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas
Anirban Maitra(The University of Texas Southwestern Medical Center), Raheela Ashfaq(Children's Medical Center)
Cited by 76
Related Papers
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
|Journal of Clinical Pathology|2000|182
Assessment of HER-2/neu Status in Breast Cancer
|American Journal of Clinical Pathology|2001|143
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
|Journal for ImmunoTherapy of Cancer|2020|91